BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Investigation
11/19/2021
Initial Lawsuit
11/19/2021
Lawsuit Progression
02/10/2022
Investigation in connection with Tenet Fintech’s registration of its common shares with the U.S. SEC, trading suspension and published short seller thesis.
09/29/2021
Tenet Fintech issues a press release announces the withdrawal of its registration statement with the SEC “while it works to comply with new SEC disclosure guidance.” Tenet referred to the guidance issued by the SEC on November 23, 2020.
“Peak’s application to list on the NASDAQ was made under the Multi-jurisdictional Disclosure System (the “MJDS”), which was jointly adopted by the SEC and the Canadian Securities Administrators. The MJDS is intended to make it easier for companies on both sides of the border to list their respective securities on exchanges in both countries. The SEC notes that the MJDS allows eligible Canadian companies to register their securities and fulfill their periodic reporting requirements by use of documents prepared in accordance with Canadian requirements and reviewed by Canadian Securities Administrators. The Company has been cooperating with the SEC and plans to submit an amended Form 40-F that highlights the concerns referenced in the Guidance as soon as practicable.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$9.09 | $9.09 | $0 | 0% |
Plaintiff brings this securities class action on behalf of persons or entities who purchased or otherwise acquired publicly traded Tenet Fintech securities between September 2, 2021 and October 13, 2021, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(1) the company did not own 51% of ASFC through Wuxi Aorong;
(2) the company did not disclose its actual ownership structure of ASFC, an undisclosed and potentially problematic nominee shareholder agreement;
(3) Huayan did not own the Heartbeat platform;
(4) the Heartbeat platform did not exist prior to the alleged acquisition;
(5) the company faced imminent delisting from NASDAQ due to non-compliance with known regulations; and
(6) as a result of the foregoing, defendants’ public statements were materially false and/or misleading at all relevant times.
02/10/2022
The court issued an order appointing the lead plaintiff and lead counsel.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.